Objective-The immunoinflammatory response plays a critical role in the development and progression of atherosclerosis.
T he immunoinflammatory response plays a prominent role in driving atherosclerotic lesion development, progression, and complications. [1] [2] [3] A large body of evidence supports an important role for T cell-mediated adaptive immunity in atherosclerosis. 4 T cells within atherosclerotic lesions show preferential expression of a limited number of TCR-variable gene segments, suggesting that a limited set of candidate antigens is responsible for specific T cells responses in atherosclerosis. 5 Several studies have shown that T helper type 1 (Th1)-driven responses predominate and are detrimental in atherosclerosis, whereas the contribution of other Th2-and Th17-related responses to disease modulation is still poorly understood. 6 Regulatory T (Treg) cells constitute a subpopulation of T cells specialized in the suppression of pathogenic responses against self or foreign antigen driven by a variety of T helper cells 7 . 8 We hypothesized several years ago that atherosclerosis may be promoted by an imbalance between regulatory and pathogenic immunity and that natural or adaptive Treg cell responses modulate a variety of T helper pathogenic responses in atherosclerosis and play a central role in counteracting disease initiation and progression. 9 We have subsequently shown that different subsets of inducible or naturally occurring Treg cells play central roles in the control of proatherogenic T cell responses and substantially limit disease development. 10 -12 These findings were corroborated by others (reviewed in 3 and 13 ) and highlighted the potential of promoting in vivo Treg cell-mediated tolerance to reduce disease development and severity. 14, 15 Solid experimental evidence indicates that mucosal administration of antigen induces antigen-specific immune toler-ance through the generation of several subsets of Treg cells 16, 17 and limits the development and progression of a variety of (auto)immune-mediated diseases. 18 Based on this evidence, several experimental studies have been conducted in the context of atherosclerosis and have demonstrated that mucosal administration of several types of atherosclerosisrelated antigens, including heat shock protein 65, 19, 20 ␤2-glycoprotein Ib, 21 oxidized low-density lipoproteins (LDL), 22 or apolipoprotein B100 (ApoB100)-derived peptides, 23 significantly reduces atherosclerotic lesion development, which is associated with features of immune modulation. The latter are very diverse and includes increases in interleukin 4 (IL-4), 20,21 IL-10, 19, 21, 23 or TGF-␤ 22 production. However, these studies did not provide experimental evidence for a direct contribution of Treg-mediated immune modulation to the atheroprotective effect.
In addition to the mucosal route, subcutaneous administration of low doses of adjuvant-free antigen has been shown to induce the generation of antigen-specific Treg cells that confer specific immune tolerance and limit the development of immune-mediated diseases. 24 Such mechanisms are thought to explain the induction of immunologic tolerance following specific allergen immunotherapy, a proven efficient treatment for allergic rhinitis and asthma, that has been practiced for several decades. 25 We hypothesized that similar to desensitization against allergens, continuous subcutaneous administration of low doses of adjuvant-free atherosclerosis-related antigen may be an attractive strategy to selectively enhance the generation of antigen-specific Treg cells and limit disease development. Recent studies have identified peptides derived from human ApoB100 molecule with immunogenic properties in humans and in mice. 26, 27 Here, we show that subcutaneous administration of low doses of these peptides without adjuvant can be used to induce a specific Treg cell response and limits both atherosclerosis development and progression in Apoe Ϫ/Ϫ mice.
Methods

Animals and Materials
We used male 12-week-old C57BL/6J Apoe Ϫ/Ϫ mice and female 36-week-old C57BL/6J Apoe Ϫ/Ϫ mice from Charles River Laboratories. All mice were on chow diet. Peptide control ovalbumin (OVA) 323 to 339 chicken Japanese quail was from Polypeptide Laboratories. The selection of human ApoB100 peptide sequences including peptide 210, peptide 240, and malondialdehyde (MDA) -P210 (KJ Ross Petersen AS, Horsholm, Denmark) was based on studies demonstrating the presence of high IgG and IgM levels against these peptide sequences in humans 27 and their immunogenic potential when used in native or MDA-modified forms and administered with adjuvant. 26, 28, 29 P210 and P240 exhibit 100% and 80% homology with the murine sequences, respectively.
Mice were implanted subcutaneously with mini-osmotic pump (Alzet1002, Charles River Laboratories) diffusing for 14 days 10 g daily of ApoB-derived peptide (3.3 g of each peptide P210, P240, MDA-P210 when in mix) or control OVA peptide. A subset of mice received intraperitoneal injection of 250 g of anti-CD25-depleting PC61 antibody (Biochem) after mini-pump implantation followed by additional injections every week. For immunization experiments, C57Bl/6J male mice (Charles River Laboratories) were immunized with 200 g of total ApoB peptides emulsified in 100 g of dimethyldioctadecylammonium bromide as adjuvant (Sigma-Al-drich). The group sizes were chosen a priori. The number of animals in each group was a compromise between the scientific needs (to detect a statistically significant difference between groups), the 3Rs (replacement, reduction, refinement) requirements, and the availability/costs of the animals. No animals died during the experimental procedures.
Size and Composition of Atherosclerotic Lesions
These studies were performed as previously described. 30 Briefly, mice were anesthetized with isoflurane before euthanization. Hearts were included in a cutting medium and frozen at -70°C. Successive 10-m transversal sections of aortic sinus were obtained. Lipids and collagen were detected using Oil Red O and Sirius Red colorations, respectively. Plaque composition was determined by use of a monoclonal rat anti-mouse macrophage antibody (clone MOMA-2 MAB1852, Chemicon) and a polyclonal goat anti-CD3 antibody (Dako). Lesion size in aortic sinus represents the whole intimal surface.
Cell Recovery and Purification
Splenocytes were obtained for purification and stimulation. CD11c ϩ cells were positively selected with anti-CD11c monoclonal antibody (Miltenyi Biotech) followed by 2 consecutive magnetic cell separations using an AutoMACS separator (Miltenyi Biotech), giving Ͼ90% CD11c ϩ cells. CD4 ϩ cells were negatively selected by use of a cocktail of antibody-coated magnetic beads from Miltenyi Biotech (anti-CD8a, anti-CD11b, anti-CD45R, anti-DX5, antiter 119), according to manufacturer's instructions. Treg cells were purified using CD4 ϩ CD25 ϩ Treg isolation kit (Miltenyi Biotech), followed by 2 consecutive magnetic cell separations using AutoMACS, according to the manufacturer's instructions, giving 85% to 90% CD4 ϩ CD25 ϩ cells. The CD4 ϩ CD25 Ϫ cells, which did not bind to the beads, were harvested from the flowthrough and contained less than 0.3% CD4 ϩ CD25 ϩ cells.
Cell Culture and Proliferation Assays
Cells were cultured in RPMI 1640 supplemented with Glutamax, 10% fetal calf serum, 0.02 mmol/L 2␤-mercaptoethanol, and antibiotics. For cytokine measurements, total splenocytes or lymph nodes cells were cultured at 10 6 cells/well and stimulated with lipopolysaccharide (1 g/mL) and recombinant interferon-␥ (100U/mL) for 48 hours. CD4 ϩ T cells were cultured at 1ϫ10 5 cells/well for 48 hours in anti-CD3-coated microplates (5 g/mL). IL-4, interferon-␥, IL-12p70, and IL-10 productions in the supernatants were measured using specific ELISAs (R&D Systems). For cell proliferation experiments, CD4 ϩ were cultured in round-bottomed 96-well microplates (total volume 200 L/well). Cells were stimulated with purified soluble CD3-specific antibody (1 g/mL, Pharmingen) in the presence of antigen-presenting cells (0.1ϫ10 5 cells) purified on CD11ccoated magnetic beads (Miltenyi Biotech).
For antigen specific regulatory function, CD4 ϩ CD25 Ϫ (2ϫ10 5 ) recovered from dimethyldioctadecylammonium bromide-immunized mice were cultured with dendritic cells (2ϫ10 4 ) and cocultured with or without CD4 ϩ CD25 ϩ cells (2ϫ10 5 ) in round-bottomed 96-well microplates (total volume 200 L/well). Cells were stimulated with ApoB100-derived peptides at 2.5 g/mL. For assessment of Treg cell suppressive function under polyclonal stimulation with anti-CD3, in the absence of antigen, experiments were performed as previously described. 12 Cells were cultured at 37°C for 72 hours and pulsed with 1 Ci of [ 3 H]thymidine (Amersham) for the last 18 hours of culture. Thymidine incorporation was assessed using a TopCount NXT scintillation counter (PerkinElmer).
Flow Cytometry
Splenocytes or lymph node cells were labeled with fluorescein isothiocyanate-conjugated anti-CD4 (clone RM4-5, eBioscience) and allophycocyanin -conjugated anti-CD25 (clone PC61.5 eBioscience) and then analyzed by flow cytometry on a CantoII flow cytometer (Becton Dickinson). Intracellular Foxp3 staining was performed using phycoerythrin-conjugated anti-mouse/rat Foxp3 (PFJK-16s, eBioscience) according to the manufacturer's instructions (eBioscience).
Real-Time Polymerase Chain Reaction
Total RNA from thoracic aorta was isolated using RNeasy Fibrous Tissue Mini Kit (Qiagen) according to manufacturer instruction. cDNA synthesis was performed with QuantiTect Reverse Transcription Kit (Qiagen). Polymerase chain reaction was performed on a StepOnePlus Real-Time PCR System (Applied Biosystems) using TaqMan Universal PCR master mix (Applied Biosystems). Mouse GAPDH was used to normalize sample amplification. The following oligonucleotides were purchased from Invitrogen: GAPDH (primers: GAPDH-R, 5Ј-CGTCCCGTAGAC AAAATGGTGAA-3Ј; GAPDH-L, 5Ј-GCCGTGAGTGGAGTCATACTGGAACA-3Ј), TGF-␤ (TGF-␤ R, 5Ј-AGCAACAATTCCTGGCGTTACCTT-3Ј; TGF-␤ L, 5Ј-TGGGCTCGTG GATCCACTTC-3Ј), and Foxp3 (forward: 5Ј-CGGCGGCCTGTTTGCAGT-3Ј; reverse: 5Ј-TTGTGGCGGATGGCATTCTTC-3Ј).
Statistical Analysis
Data are expressed as meanϮSEM. For atherosclerotic plaque size, data were compared and intergroup differences were analyzed with 1-way ANOVA and post hoc Bonferroni test. Others data were analyzed by a 2-tailed Student t test. Nonparametric distributions were analyzed using Kruskal-Wallis and Mann-Whitney tests. Differences were considered statistically significant when the probability value was Ͻ0.05.
Results
Continuous Subcutaneous Infusion of Adjuvant-Free ApoB100-Derived Peptides to Apoe ؊/؊ Mice Reduces the Development of Atherosclerosis
We first examined the effect of continuous subcutaneous infusion via osmotic pump of a mixture of the 3 ApoB100derived peptides (P210, MDA-P210, and P240) on the development of atherosclerosis in Apoe Ϫ/Ϫ mice. Male 12-weekold Apoe Ϫ/Ϫ mice were infused with the peptides or an equal amount of control OVA peptide for 2 weeks and were euthanized at 22 weeks of age to assess lesion development. Infusion with ApoB100 peptides led to a marked Ϸ40% reduction of lesion development compared with the OVA group (Pϭ0.0005; Figure 1 ). Infusion of the only P210 peptide led to a significant Ϸ30% reduction of lesion size (Pϭ0.0136, Figure 1 ), suggesting a major role for this peptide in the atheroprotective effect. The reduction of atherosclerosis was independent of circulating cholesterol levels (5.68Ϯ0.41, 5.04Ϯ0.36, and 5.59Ϯ0.4 g/L in the OVA, P210, and ApoB100 groups, respectively).
Continuous Subcutaneous Infusion of Adjuvant-Free ApoB100-Derived Peptides to Apoe ؊/؊ Mice Inhibits the Progression of Established Atherosclerosis and Promotes Features of Plaque Healing
To assess the effect of ApoB100 peptides on the development of advanced atherosclerosis, 36-week old female Apoe Ϫ/Ϫ mice with advanced established atherosclerotic lesions (Figure 2, T0) received the same 2-week infusion of OVA or ApoB100 peptides, and mice were killed at 46 weeks of age. Ten weeks after the start of the infusion, lesion size was significantly reduced in mice treated with ApoB100 peptides compared with OVA-treated animals (Pϭ0.0023; Figure 2 ). Again, the difference of lesion size between the groups was independent of circulating cholesterol levels (4.28Ϯ0.31 and 3.89Ϯ0.15 g/L in the OVA and ApoB100 groups, respectively, Pϭ0. 22) .
We also examined the impact of treatment with ApoB100 peptides on the composition of these advanced lesions. Lesion macrophage content did not differ between OVA and ApoB100 groups (Pϭ0.5). However, reduction of atherosclerosis in mice treated with ApoB100 peptides was associated with a 45% reduction of lesional T cell infiltration (Pϭ0.009; Figure 2 ) and a 22% increase of collagen content (PϽ0.05; Figure 2 ). These results clearly show that continuous subcutaneous infusion of adjuvant-free ApoB100 peptides reduces both early and advanced lesion development and promotes features of plaque healing. Atheroprotection was observed in the absence of any significant change in IgG or IgM antibody levels against oxidized LDL ( Figure I in the online-only Data Supplement).
Treatment of Apoe ؊/؊ Mice With ApoB100 Peptides Reduces T-Cell Activation
We next examined cytokine production by total or CD4 ϩ spleen and lymph node cells recovered from OVA-or ApoB100-treated Apoe Ϫ/Ϫ mice. We found that splenocytes with ApoB100 peptides reduced T cell cytokine production to levels seen in nonatherosclerotic Apoe ϩ/ϩ mice of similar age (data not shown), indicating an important control of the adaptive immune response through tolerization with ApoB100 peptides.
Induction of Treg Cells Plays a Central Role in ApoB100-Mediated Immune Modulation and Atheroprotection
We next examined the role of Treg cells in mediating the effects of ApoB100-derived peptides. Analysis of Treg cell population (CD4 ϩ CD25 ϩ Foxp3 ϩ ) by flow cytometry showed a significant Ϸ30% increase of Treg cells in the lymph nodes of Apoe Ϫ/Ϫ mice treated with ApoB100 peptides compared with OVA-treated mice (Pϭ0.04; Figure 4 ). The increase of Treg cells in the spleen of ApoB100-treated mice did not reach statistical significance (Figure 4) . These findings were consistent with the significant reduction of the proliferation of lymph node-derived but not spleen-derived CD4 ϩ cells after anti-CD3 stimulation in vitro (Figure 4) . We then assessed the ability of Treg cells recovered from either OVA-or ApoB100-tolerized Apoe Ϫ/Ϫ mice to suppress the proliferation of T effector CD4 ϩ CD25 Ϫ cells recovered from ApoB100-sensitized (immunization with adjuvant) Apoe Ϫ/Ϫ mice. As shown in Figure 4 , T effector cell proliferation was suppressed only after coculture with Treg cells recovered from ApoB100-tolerized animals in the presence of antigen (ApoB100 peptides). Interestingly, Tregs did not suppress T effector cell proliferation in the absence of antigen ( Figure IV Finally, we assessed the direct contribution of Treg cells to atheroprotection in ApoB100-tolerized Apoe Ϫ/Ϫ mice. Additional mice were infused with either OVA or ApoB100 peptides but now also received an intraperitoneal injection of depleting anti-CD25 antibody every week. The experiment was repeated twice ( Figure VI in the online-only Data Supplement; Figure 5 ). Treg depletion abrogated the atheroprotective and immunomodulatory effects of ApoB100mediated tolerization ( Figure VI in the online-only Data Supplement; Figure 5 ). Overall, our findings strongly suggest that continuous subcutaneous infusion of adjuvant-free ApoB100 peptides reduces atherosclerosis by promoting a specific Treg cell response.
Discussion
Previous studies have reported atheroprotective effects of mucosal administration of atherosclerosis-related antigens and have suggested that the protection was mediated through the induction of immunologic tolerance. 19 -23 Our present study is the first to provide direct evidence for the involvement of antigen-specific Treg cells in mediating the protective effect of a tolerization strategy to treat atherosclerosis. Continuous subcutaneous delivery of adjuvant-free ApoB100 peptides reduced both the development of early lesions and the progression of advanced atherosclerosis while inducing features of plaque stability. Thus, the novel immunomodulatory and atheroprotective strategy described here appears to be potentially relevant to the clinical situation in humans.
Several observations in the present work indicate that the atheroprotective effect involved the induction of immunologic tolerance through the promotion of specific Treg cells.
Atheroprotection was associated with a marked reduction of T cell proliferation and infiltration within the lesions and with substantial decrease of both Th1-and Th2-related cytokines, highly suggestive of an immunoregulatory effect. In addition, Th1 and Th2 cytokine production of Apoe Ϫ/Ϫ mice was reduced to levels seen in nonatherosclerotic C57Bl/6 mice, indicating that ApoB100 peptide-based therapy abrogates excessive activation of the T cell response of Apoe Ϫ/Ϫ mice without unfavorably affecting T cell homeostasis of healthy normocholesterolemic mice.
Based on these results and on previous data showing that continuous subcutaneous infusion of low doses of adjuvantfree antigen generates antigen-specific Treg cells, 24 we assessed Treg cell function in our sets of treated Apoe Ϫ/Ϫ mice. Several lines of evidence indicate that atheroprotection of ApoB100-treated mice was mediated by a specific population of Treg cells. The percentage of CD4 ϩ CD25 ϩ Foxp3 ϩ Treg cells significantly increased in the lymph nodes of Apoe Ϫ/Ϫ mice infused with ApoB100 peptides compared with OVAtreated animals, which is consistent with the reduced proliferation of lymph node-derived T cells and with the suppres- sion of excessive T cell cytokine production. The increase of Treg cells in lymph nodes of ApoB100-treated animals cannot entirely be accounted for by an increase of ApoB100 peptides-specific Treg cell population. However, we do show that such antigen-specific Treg cells were induced following ApoB100-based therapy because CD4 ϩ CD25 ϩ Treg cells recovered from lymph nodes and spleens of ApoB100-treated Apoe Ϫ/Ϫ mice significantly suppressed antigen-specific T effector cell proliferation in vitro. Finally, Treg cell depletion abrogated both the immunomodulatory and atheroprotective effects of ApoB100 peptides, providing direct evidence for the critical requirement of Treg cells to control proatherogenic immunity and disease development using this therapeutic strategy. It should be noted that Treg cell depletion did not alter lesion size in the control OVA-treated group. We speculate that this might be due to alteration of Treg function in adult Apoe Ϫ/Ϫ mice (used here between 12 and 22 weeks of age) compared with previous studies 12 that used young Apoe Ϫ/Ϫ mice (starting depletion at 6 weeks of age). It should also be noted that we did not assess the in vitro function of Tregs derived from OVA-tolerized mice after stimulation with OVA in vitro. However, the results of this latter experiment would not have altered our conclusion that tolerization with ApoB100 peptides induced an atheroprotective Treg cell response.
Previous investigators have used the subcutaneous route to modulate immune responses in the context of atherosclerosis. However, those studies have associated the administered atherosclerosis-related antigen with a variety of adjuvants, leading to the generation of both humoral and cellular immune responses with variable outcomes on atherosclerosis. Immunization of Ldlr Ϫ/Ϫ mice with MDA-LDL induced both adaptive T cell-dependent and innate T cell-independent type 2 immune responses and protected from atherosclerosis, in part through the production of natural IgM antibodies specific for oxidized LDL. 31 Immunization with native, oxidized LDL [32] [33] [34] [35] or with ApoB100-derived peptides 26 reduced lesion development by mechanisms that are not fully understood. In contrast, immunization of rabbits or mice with heat shock protein-65 36, 37 or ␤2-glycoprotein Ib 38 promoted atherosclerotic lesion development, most probably through the induction of pathogenic T cell immunity. 39, 40 A more recent study 40 suggested that immunization of Apoe Ϫ/Ϫ mice with P210 peptide (used with bovine serum albumin and aluminum hydroxide) was associated with a strong increase in CD4 ϩ Foxp3 ϩ cells and a reduction of atherosclerosis. However, there was no evidence that peptide-specific Treg cells were generated after P210 immunization, and there was still the possibility that the increase of Treg cell population was mediated by aluminum hydroxide alone, previously shown to promote Treg cells in the absence of any peptide adjunction. 41 Our proposed strategy shows a peptide-specific induction of Treg cells, avoids the use of adjuvants, and therefore reduces the risk of undesirable immunostimulatory effects that might counteract the immunomodulatory potential of the administered antigen. It also offers the advantage of downregulating the excessive immune response in an antigen-specific manner. Whether this novel immunomodulatory strategy will also be successful with atherosclerosis-related antigens other than those derived from ApoB100 merits further investigation.
In conclusion, we believe that we have identified a novel and attractive strategy for immunoprotection against atherosclerosis based on subcutaneous delivery of low doses of adjuvant-free antigens, here ApoB100-derived peptides that reduce both atherosclerosis development and atherosclerosis progression in mice through the promotion of antigenspecific Treg cells. Additional studies will be required to fully delineate the mechanisms by which Treg cells modulate the atherosclerotic process and the mechanisms that control their maintenance in vivo in this context.
